Trial Profile
A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone as Post Autologous Transplant Consolidation in Patients With High-risk Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary) ; Pembrolizumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 28 Jul 2023 Time frame changed from 12 Months to Up to 3 years.
- 28 Jul 2023 Status changed from active, no longer recruiting to discontinued (FDA Hold Due to Updated Risks).
- 18 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Oct 2022.